Santa Ana Bio Advances SAB01 Into Phase 1
ALAMEDA, Calif. — September 14, 2026 Santa Ana Bio announced that the first cohort has been dosed in the...
Autoimmune Disease
Advertisement
AbelZeta’s C-CAR168 Receives FDA IND Clearance
San Diego, California, U.S., September 14, 2026 AbelZeta Therapeutics has announced that the U.S. Food and Drug Administration (FDA)...
Genentech Gains FDA Priority Review for Enspryng in MOGAD
SOUTH SAN FRANCISCO, Calif. — September 9, 2026 Genentech, a member of the Roche Group, announced that the U.S....
Roche Wins FDA Priority Review for Enspryng in MOGAD
BASEL, Switzerland — September 10, 2026 Roche announced that the U.S. Food and Drug Administration (FDA) granted Priority Review...
Beeline Medicines Advances Afimetoran Toward Pivotal Lupus Trials
STAMFORD, Conn. — September 9, 2026 Beeline Medicines Corporation announced positive topline results from its global Phase 2 study...
Advertisements
Fate Therapeutics Presents FT819 Clinical Data at CCR-West 2026
SAN DIEGO — September 9, 2026 Fate Therapeutics, Inc. announced that new clinical data for its off-the-shelf anti-CD19 CAR...
Accro Bioscience Gains NMPA Clearance for AC-201 Vitiligo Trial
New York and Suzhou, China, September 8, 2026 Accro Bioscience has announced a major clinical development milestone for AC-201,...
Vor Bio Completes Phase 3 UPSTREAM MG Enrollment and Expands Telitacicept Into Ocular MG
BOSTON, Massachusetts — September 8, 2026 Vor Bio announced the completion of enrollment in UPSTREAM MG, its global Phase...
Monte Rosa Advances MRT-6160 Into Phase 2 for Sjögren’s Disease
BOSTON, Massachusetts — September 8, 2026 Monte Rosa Therapeutics, Inc. announced that Novartis has initiated a global Phase 2...
Nkarta to Present Initial NKX019 Autoimmune Data at ACR 2026
SOUTH SAN FRANCISCO, California — September 8, 2026 Nkarta, Inc. announced that three scientific presentations featuring NKX019 have been...
Advertisement
